Remodeling gut microbiota by Clostridium butyricum (C.butyricum) attenuates intestinal injury in burned mice. 2020

Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
Department of Burns and Cutaneous Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China.

The dysbiosis of gastrointestinal microbiome is an important reason for burn-induced intestinal injury. Clostridium butyricum (C.butyricum) and its production butyrate are beneficial for the homeostasis of intestinal microflora and suppression of inflammatory response. The roles of C.butyricum and butyrate in burn-induced intestinal injury were explored. The effects of oral administration of C.butyricum on intestinal injury were observed in burned mice. The skin surface of mice was exposed to 95 °C water to induce a burn injury. Then the intestinal microbiome structure, abundance of C.butyricum and level of butyrate were respectively observed. The correction between intestinal permeability indicated by FITC dextran level and abundance of C.butyricum or level of butyrate was analyzed. C.butyricum was cultured and orally administrated to burned mice. The levels of butyrate, FITC dextran and pro-inflammatory cytokines, including interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) were respectively measured. Burn injury altered the intestinal microbiome structure of mice, and especially decreased the abundance of C.butyricum and level of butyrate. Both the abundance of C.butyricum and the level of butyrate were negatively correlated with the intestinal permeability. Oral administration of C.butyricum increased the level of butyrate, decreased levels of TNF-α and IL-6, and suppressed intestinal damage in burn-injured mice. Oral administration of C.butyricum significantly alleviated the intestinal damage induced by burn injury. The therapeutic effects of C.butyricum and butyrate on burn injury should be further explored, which deserves further investigation.

UI MeSH Term Description Entries
D007413 Intestinal Mucosa Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI. Intestinal Epithelium,Intestinal Glands,Epithelium, Intestinal,Gland, Intestinal,Glands, Intestinal,Intestinal Gland,Mucosa, Intestinal
D007421 Intestine, Small The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM. Small Intestine,Intestines, Small,Small Intestines
D010539 Permeability Property of membranes and other structures to permit passage of light, heat, gases, liquids, metabolites, and mineral ions. Permeabilities
D002056 Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like. Burn
D002087 Butyrates Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. Butyrate,n-Butyrate,Butanoic Acids,Butyric Acids,Acids, Butanoic,Acids, Butyric,n Butyrate
D003911 Dextrans A group of glucose polymers made by certain bacteria. Dextrans are used therapeutically as plasma volume expanders and anticoagulants. They are also commonly used in biological experimentation and in industry for a wide variety of purposes. Dextran,Dextran 40,Dextran 40000,Dextran 70,Dextran 75,Dextran 80,Dextran B-1355,Dextran B-1355-S,Dextran B1355,Dextran B512,Dextran Derivatives,Dextran M 70,Dextran T 70,Dextran T-40,Dextran T-500,Hemodex,Hyskon,Infukoll,Macrodex,Polyglucin,Promit,Rheodextran,Rheoisodex,Rheomacrodex,Rheopolyglucin,Rondex,Saviosol,Dextran B 1355,Dextran B 1355 S,Dextran T 40,Dextran T 500
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000069196 Gastrointestinal Microbiome All of the microbial organisms that naturally exist within the GASTROINTESTINAL TRACT. Enteric Bacteria,Gastric Microbiome,Gastrointestinal Flora,Gastrointestinal Microbial Community,Gastrointestinal Microbiota,Gastrointestinal Microflora,Gut Flora,Gut Microbiome,Gut Microbiota,Gut Microflora,Intestinal Flora,Intestinal Microbiome,Intestinal Microbiota,Intestinal Microflora,Bacteria, Enteric,Flora, Gastrointestinal,Flora, Gut,Flora, Intestinal,Gastric Microbiomes,Gastrointestinal Microbial Communities,Gastrointestinal Microbiomes,Gastrointestinal Microbiotas,Gut Microbiomes,Gut Microbiotas,Intestinal Microbiomes,Intestinal Microbiotas,Microbial Community, Gastrointestinal,Microbiome, Gastric,Microbiome, Gastrointestinal,Microbiome, Gut,Microbiome, Intestinal,Microbiota, Gastrointestinal,Microbiota, Gut,Microbiota, Intestinal,Microflora, Gastrointestinal,Microflora, Gut,Microflora, Intestinal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
July 2016, Brain research,
Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
January 2022, Bioscience of microbiota, food and health,
Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
March 2023, Food chemistry,
Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
February 2024, Food & function,
Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
November 2020, International immunopharmacology,
Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
January 2021, Frontiers in microbiology,
Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
January 2019, Frontiers in immunology,
Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
March 2023, iScience,
Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
January 2022, Frontiers in microbiology,
Dongliang Zhang, and Cailin Zhu, and Zhuoqun Fang, and Hairui Zhang, and Jinglin Yang, and Ke Tao, and Dahai Hu, and Juntao Han, and Xuekang Yang
March 2024, Journal of translational medicine,
Copied contents to your clipboard!